Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData Read more
Lupin, Zydus sign licensing pact to co-market Saroglitazar Mg for chronic liver diseases in India Read more
HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData Read more
Zydus announces Phase IV EVIDENCES-XI trial to generate RWE of Saroglitazar Mg in NAFLD patients with comorbidities Read more
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData Read more